Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743758 | 0.87 | DYRK1A (0.37) | CYP11B1CYP11B2JAK2DYRK1ARPS6KA3 | |
| SCHEMBL20743006 | 0.82 | JAK2 (0.40) | JAK2BACE1BACE2RPS6KA3PIK3CA | |
| SCHEMBL20754791 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2MKNK1MKNK2DYRK1A | |
| SCHEMBL20609816 | 0.77 | JAK2 (0.45) | CYP11B1CYP11B2JAK2MKNK1MKNK2 | |
| SCHEMBL20743855 | 0.76 | IKBKB (0.43) | RPS6KA3 | |
| SCHEMBL20743713 | 0.72 | MET (0.34) | — | |
| SCHEMBL20754892 | 0.72 | METAP2 (0.37) | JAK2 | |
| SCHEMBL20743756 | 0.71 | TDO2 (0.44) | MKNK2RPS6KA3PIK3CA | |
| SCHEMBL20754515 | 0.71 | ALOX5AP (0.42) | PIK3CA | |
| SCHEMBL19474940 | 0.70 | HRH4 (0.35) | RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| EP-3668861-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| CN-111132974-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | CYP11B1 160/4885CYP11B2 177/4885IDH1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.